NR3C2 and chronic kidney disease: In the Munich Wistar Frömter rat, a CKD model with reduced nephron numbers, a non-steroidal MR antagonist, finerenone, reverses endothelial dysfunction through increased nitric oxide availability and the upregulation of superoxide dismutase activity [121].